Your session is about to expire
← Back to Search
CAR-T Cell Therapy for HIV
Study Summary
This trial will test a new treatment for HIV that involves modifying a patient's own T cells to attack the virus. The treatment will be given in escalating doses to see what is safe and effective.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have a long-term liver condition.I am infected with HIV-1.I have had a cancer linked to HIV, like Kaposi's sarcoma or lymphoma.I've been on stable HIV treatment for over a year without breaks longer than 2 weeks.I have a current or past infection of hepatitis B.I have a history of ART treatment and can follow an effective antiretroviral regimen.I am willing to stop my current HIV treatment for the study.I am between 18 and 65 years old.I have tuberculosis.I have an active hepatitis C infection.I have heart disease that is not well-managed.My HIV treatment includes long-lasting drugs that work even if I stop taking them for up to a year.My HIV treatment includes protease inhibitors or AZT.
- Group 1: Low Dose CAR-T Cells Only
- Group 2: Conditioning + Low Dose CAR-T Cells
- Group 3: Conditioning + High Dose CAR-T Cells
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Would this particular experiment be open to individuals who are octogenarians?
"The age bracket for patients that this trial is recruiting falls between 18-65 years old."
To whom is this trial available?
"The current prerequisites for this study are that patients must have hiv infections and be between 18-65 years old. Right now, the trial is enrolling approximately 18 individuals."
How many people are able to join this clinical trial?
"That is correct. The public information available on clinicaltrials.gov shows that this study has not yet reached its patient quota and is actively looking for test subjects. This trial was posted on March 1st, 2021 and updated May 17th, 2022. They are 18 patients remaining to be recruited between 2 hospitals."
Are there any places open in this clinical trial for new participants?
"From what is detailed on clinicaltrials.gov, this particular trial is looking for more participants. The listing was first put up on 3/1/2021 and updated as recently as 5/17/2022."
What type of cancer does LVgp120duoCAR-T cells, low dose usually help to improve?
"Multiple sclerosis, mixed-cell type lymphoma, and leukemia, myelocytic, acute can all be treated using low dose LVgp120duoCAR-T cells."
Share this study with friends
Copy Link
Messenger